Vitasora Health Limited · ASX:VHL

Vitasora Health — Respiri — Corporate Update (July 2019)

13 slides from Vitasora Health's corporate update, Jul 25, 2019

  1. Slide 1: Investor Update

    A Breath of Fresh Ideas INVESTOR UPDATE 25 JULY 2019

  2. Slide 2: Transition to Launch Phase

    TRANSITION TO LAUNCH PHASE ▪ wheezoTM Production ▪ CE Mark ▪ Clinical Validation ▪ India Summary ▪ India Market Traction ▪ wheezo appTM launch ▪ 2020 Transformation 02

  3. Slide 3: wheezo Production

    WHEEZOTM PRODUCTION Building Supply Capacity ▪ wheezoTM breath sensor design complete ▪ Supply chain management – forecasting, planning, procurement, strategic sourcing in progress ▪ First batch of 500 planned for production at SRX Dandenong to optimize assembly process ▪ Transfer of production to S

  4. Slide 4: CE Mark & TGA Approval

    CE MARK & TGA APPROVAL STAGE DATE wheezoTM Safety & Compliance Testing July – September 2019 wheezoTM Technical File submission to Notified Body (DQS Germany) October 2019 Stage 2 Audit (System Assessment) Respiri Quality Management System October 2019 DQS Report (System Evaluation) ISO 13485 + MDD

  5. Slide 5: Clinical Validation

    CLINICAL VALIDATION Building credibility with the medical community ▪ Professor Bruce Thompson has attracted leading peers to join Medical & Scientific Advisory Board in Australia ▪ Study 1 Eastern Health (Stethoscope Comparison) is ongoing with abstract submitted to British Thoracic Society last we

  6. Slide 6: India Summary

    INDIA SUMMARY ▪ Initial target markets in Delhi, Mumbai, Chennai, Bangalore ▪ Working towards supply of 20,000 wheezoTM units per month ▪ Investigating manufacturing suppliers in India supported by experienced JV partner with office in Noida - Special Economic Zone (SEZ) ▪ Working towards B2B orders

  7. Slide 7: India Market Traction

    INDIA MARKET TRACTION ▪ Engaged with 20 leading pulmonologists/heads of department driving product awareness to be leveraged through more than 200 Tier 1 hospitals ▪ Provides opportunity for large B2B hospital sales and access to 15m+ respiratory patients per year (200 hospitals x average 5 pulmonol

  8. Slide 8: wheezo App Launch

    WHEEZOTM APP LAUNCH ▪ Launching in Australian Asthma Week, September 1 – 7, 2019 ▪ wheezoTM app with self assessment, medication log and history ▪ Promote app via established social channels with call to action on wheezo.com website ▪ Helps establish wheezoTM brand and prepares customers for wheeze

  9. Slide 9: FY 2020 Key Milestones

    FY 2020 KEY MILESTONES AUG 2019 • Finalise and Launch of key pilot studies in India – focus on leading hospitals and Government-supported health initiatives around respiratory disease SEP 2019 • Establish manufacturing and supply chain plan in response to demand from India • Increasing the healthcar

  10. Slide 10: Use of Funds | July Placement

    USE OF FUNDS | JULY 19 PLACEMENT 1. Payments to key suppliers – Grey Innovation (technology), Two Bulls (software and app development) and SRX (manufacturer). 2. Establish manufacturing and supply chain processes to meet initial orders and demand from India 3. Working capital for initial production

  11. Slide 11: Transformation in 2020

    TRANSFORMATION IN 2020 ▪ While building up supply capacity, continue momentum in India via a series of pilots, demonstrating the large demand waiting for wheezoTM ▪ Initial objective of 20,000 units per month supply (Indian market), and then incrementally increasing further ▪ CE mark, clinical valid

  12. Slide 12: Forward Looking Statements

    Forward Looking Statements Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its be

  13. Slide 13: Respiri Limited (The Company) Risk Factors

    Respiri Limited (The Company) Risk Factors This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. Speculative nature of investment An inv

Respiri — Corporate Update (July 2019) on 6ix